{
    "id": 3828,
    "fullName": "PIK3CA H1047L",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "PIK3CA H1047L is a hotspot mutation that lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). H1047L results in increased phosphorylation of Akt and Mek1/2, growth factor-independent cell survival, and transformation in cell culture (PMID: 26627007, PMID: 29533785).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                },
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5290,
        "geneSymbol": "PIK3CA",
        "terms": [
            "PIK3CA",
            "CLAPO",
            "CLOVE",
            "CWS5",
            "MCAP",
            "MCM",
            "MCMTC",
            "p110-alpha",
            "PI3K",
            "PI3K-alpha"
        ]
    },
    "variant": "H1047L",
    "createDate": "03/17/2015",
    "updateDate": "02/07/2020",
    "referenceTranscriptCoordinates": {
        "id": 171852,
        "transcript": "NM_006218",
        "gDna": "chr3:g.179234297A>T",
        "cDna": "c.3140A>T",
        "protein": "p.H1047L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4236,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 3636,
                "profileName": "PIK3CA H1047L"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4257,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 3636,
                "profileName": "PIK3CA H1047L"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4222,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 3636,
                "profileName": "PIK3CA H1047L"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4229,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 3636,
                "profileName": "PIK3CA H1047L"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4250,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 3636,
                "profileName": "PIK3CA H1047L"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4243,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 3636,
                "profileName": "PIK3CA H1047L"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8581,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment resulted in tumor growth stabilization in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D, PIK3CA E545K and H1047L (PMID: 26272063).",
            "molecularProfile": {
                "id": 26369,
                "profileName": "KRAS G12D PIK3CA E545K PIK3CA H1047L TP53 wild-type"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8902,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047L resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26531,
                "profileName": "PIK3CA H1047L PIM1 over exp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8912,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to BX-795 in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26531,
                "profileName": "PIK3CA H1047L PIM1 over exp"
            },
            "therapy": {
                "id": 3467,
                "therapyName": "BX-795",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13079,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047L (PMID: 29208673).",
            "molecularProfile": {
                "id": 28996,
                "profileName": "ERBB2 over exp PIK3CA H1047L"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10846,
                    "pubMedId": 29208673,
                    "title": "Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29208673"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17133,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047L (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34226,
                "profileName": "ESR1 pos PIK3CA H1047L"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19579,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047L (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34235,
                "profileName": "PGR pos PIK3CA H1047L"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20818,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a colorectal cancer patient demonstrated resistance to treatment with Erbitux (cetuximab) and was found to harbor EGFR S492R, KRAS Q61H, and PIK3CA H1047L (PMID: 31924740).",
            "molecularProfile": {
                "id": 35350,
                "profileName": "EGFR S492R KRAS Q61H PIK3CA H1047L"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18062,
                    "pubMedId": 31924740,
                    "title": "KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31924740"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3636,
            "profileName": "PIK3CA H1047L",
            "profileTreatmentApproaches": [
                {
                    "id": 17220,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "PIK3CA H1047L"
                },
                {
                    "id": 17217,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PIK3CA H1047L"
                },
                {
                    "id": 17218,
                    "name": "mTOR Inhibitor",
                    "profileName": "PIK3CA H1047L"
                },
                {
                    "id": 17216,
                    "name": "Akt2 Inhibitor",
                    "profileName": "PIK3CA H1047L"
                },
                {
                    "id": 17222,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "PIK3CA H1047L"
                },
                {
                    "id": 17221,
                    "name": "Akt1 Inhibitor",
                    "profileName": "PIK3CA H1047L"
                },
                {
                    "id": 17219,
                    "name": "PIK3CA inhibitor",
                    "profileName": "PIK3CA H1047L"
                },
                {
                    "id": 17215,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "PIK3CA H1047L"
                }
            ]
        },
        {
            "id": 26369,
            "profileName": "KRAS G12D PIK3CA E545K PIK3CA H1047L TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26531,
            "profileName": "PIK3CA H1047L PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28959,
            "profileName": "ERBB2 pos PIK3CA H1047L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28996,
            "profileName": "ERBB2 over exp PIK3CA H1047L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34226,
            "profileName": "ESR1 pos PIK3CA H1047L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34235,
            "profileName": "PGR pos PIK3CA H1047L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35350,
            "profileName": "EGFR S492R KRAS Q61H PIK3CA H1047L",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 171853,
            "transcript": "XM_011512894",
            "gDna": "chr3:g.179234297A>T",
            "cDna": "c.3140A>T",
            "protein": "p.H1047L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171851,
            "transcript": "XM_006713658",
            "gDna": "chr3:g.179234297A>T",
            "cDna": "c.3140A>T",
            "protein": "p.H1047L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171852,
            "transcript": "NM_006218",
            "gDna": "chr3:g.179234297A>T",
            "cDna": "c.3140A>T",
            "protein": "p.H1047L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}